JP2005529934A5 - - Google Patents

Download PDF

Info

Publication number
JP2005529934A5
JP2005529934A5 JP2004509683A JP2004509683A JP2005529934A5 JP 2005529934 A5 JP2005529934 A5 JP 2005529934A5 JP 2004509683 A JP2004509683 A JP 2004509683A JP 2004509683 A JP2004509683 A JP 2004509683A JP 2005529934 A5 JP2005529934 A5 JP 2005529934A5
Authority
JP
Japan
Prior art keywords
compound
group
alkyl
formula
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004509683A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005529934A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/017042 external-priority patent/WO2003101992A1/en
Publication of JP2005529934A publication Critical patent/JP2005529934A/ja
Publication of JP2005529934A5 publication Critical patent/JP2005529934A5/ja
Pending legal-status Critical Current

Links

JP2004509683A 2002-05-31 2003-05-30 キサンチンホスホジエステラーゼvインヒビターおよびその前駆物質を調製するプロセス Pending JP2005529934A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38447802P 2002-05-31 2002-05-31
PCT/US2003/017042 WO2003101992A1 (en) 2002-05-31 2003-05-30 Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof

Publications (2)

Publication Number Publication Date
JP2005529934A JP2005529934A (ja) 2005-10-06
JP2005529934A5 true JP2005529934A5 (US07786301-20100831-C00009.png) 2006-07-06

Family

ID=29712039

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004509683A Pending JP2005529934A (ja) 2002-05-31 2003-05-30 キサンチンホスホジエステラーゼvインヒビターおよびその前駆物質を調製するプロセス

Country Status (17)

Country Link
US (2) US7074923B2 (US07786301-20100831-C00009.png)
EP (1) EP1509525B9 (US07786301-20100831-C00009.png)
JP (1) JP2005529934A (US07786301-20100831-C00009.png)
CN (2) CN100497336C (US07786301-20100831-C00009.png)
AR (1) AR040232A1 (US07786301-20100831-C00009.png)
AT (1) ATE336494T1 (US07786301-20100831-C00009.png)
AU (1) AU2003238822A1 (US07786301-20100831-C00009.png)
CA (1) CA2483923A1 (US07786301-20100831-C00009.png)
CY (1) CY1105774T1 (US07786301-20100831-C00009.png)
DE (1) DE60307628T2 (US07786301-20100831-C00009.png)
DK (1) DK1509525T5 (US07786301-20100831-C00009.png)
ES (1) ES2270047T3 (US07786301-20100831-C00009.png)
HK (1) HK1068139A1 (US07786301-20100831-C00009.png)
MX (1) MXPA04011862A (US07786301-20100831-C00009.png)
PT (1) PT1509525E (US07786301-20100831-C00009.png)
WO (1) WO2003101992A1 (US07786301-20100831-C00009.png)
ZA (1) ZA200408719B (US07786301-20100831-C00009.png)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
EA007485B1 (ru) * 2001-02-24 2006-10-27 Берингер Ингельхайм Фарма Гмбх Унд Ко. Кг Производные ксантина, способ их получения, фармацевтическая композиция на их основе и способ ее получения
DE60319980T2 (de) * 2002-05-31 2009-04-16 Schering Corporation Xanthin-phosphodiesterase-v-hemmer polymorphe
WO2004009091A1 (en) * 2002-06-17 2004-01-29 Glaxo Group Limited Purine derivatives as liver x receptor agonists
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7495005B2 (en) * 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US7569574B2 (en) 2002-08-22 2009-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7482337B2 (en) * 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10254304A1 (de) * 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
US7566707B2 (en) 2003-06-18 2009-07-28 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
CN1860119A (zh) * 2003-07-31 2006-11-08 先灵公司 用于治疗勃起功能障碍的黄嘌呤磷酸二酯酶5抑制剂代谢物及其衍生物
KR20060101762A (ko) * 2003-11-21 2006-09-26 쉐링 코포레이션 포스포디에스테라제 v 억제제 제형
DE10355304A1 (de) * 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004009039A1 (de) * 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
US7393847B2 (en) * 2004-03-13 2008-07-01 Boehringer Ingleheim International Gmbh Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
US7179809B2 (en) * 2004-04-10 2007-02-20 Boehringer Ingelheim International Gmbh 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
US7439370B2 (en) 2004-05-10 2008-10-21 Boehringer Ingelheim International Gmbh Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
DE102004030502A1 (de) * 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004043944A1 (de) * 2004-09-11 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004044221A1 (de) * 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CA2810839A1 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh A polymorphic form of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(r)-amino-piperidin-1-yl)-xanthine
PE20110235A1 (es) * 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP2057160A1 (en) * 2006-08-08 2009-05-13 Boehringer Ingelheim International GmbH Pyrrolo [3, 2 -d]pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus
AU2008290582B2 (en) * 2007-08-17 2014-08-14 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
MX2011001525A (es) * 2008-08-15 2011-03-29 Boehringer Ingelheim Int Derivados de purina para su uso en el tratamiento de enfermedades relacionadas con fab.
CN102149407A (zh) 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 治疗糖尿病和相关病症的组合疗法
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
BRPI0923121A2 (pt) 2008-12-23 2015-08-11 Boehringer Ingelheim Int Formas salinas de compostos orgânico
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
CN107115530A (zh) 2009-11-27 2017-09-01 勃林格殷格翰国际有限公司 基因型糖尿病患者利用dpp‑iv抑制剂例如利拉利汀的治疗
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
CN102971005A (zh) 2010-06-24 2013-03-13 贝林格尔.英格海姆国际有限公司 糖尿病治疗
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EP3517539B1 (en) 2011-07-15 2022-12-14 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Dpp−4阻害薬の医学的使用
CA3022202A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903224B2 (en) * 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
US5064825A (en) * 1989-06-01 1991-11-12 Merck & Co., Inc. Angiotensin ii antagonists
JPH0372480A (ja) * 1989-08-10 1991-03-27 Hokuriku Seiyaku Co Ltd キサンチン誘導体及びそれらを有効成分とする気管支拡張剤
CA2030112A1 (en) 1989-11-24 1991-05-25 Yasuo Ito Xanthine compound, method for preparing thereof, and a pharmaceutical composition comprising the same
NZ238609A (en) * 1990-06-21 1993-12-23 Schering Corp Polycyclic guanine derivatives; preparation, pharmaceutical compositions,
JPH04128285A (ja) * 1990-06-27 1992-04-28 Hokuriku Seiyaku Co Ltd キサンチン誘導体
JPH04279586A (ja) * 1991-03-05 1992-10-05 Hokuriku Seiyaku Co Ltd キサンチン誘導体
JPH051065A (ja) * 1991-06-20 1993-01-08 Hokuriku Seiyaku Co Ltd キサンチン誘導体
EP0538194B1 (de) * 1991-10-17 1997-06-04 Novartis AG Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
DE4411660A1 (de) 1994-04-05 1995-10-12 Hoechst Ag Verwendung von Xanthinderivaten zur Reduktion der pathologischen Hyperreagibilität eosinophiler Granulozyten, neue Xanthinverbindungen und Verfahren zu deren Herstellung
DE19540798A1 (de) 1995-11-02 1997-05-07 Hoechst Ag Alkylxanthinphosphonate und Alkylxanthinphosphinoxide und deren Verwendung als Arzneimittel
SI0812844T1 (en) * 1996-06-07 2003-02-28 Hoechst Aktiengesellschaft Use of theophyllin derivatives for the treatment and prophylaxis fo shock conditions, novel xanthine compounds and processes for the production thereof
AU2001268958B2 (en) * 2000-07-04 2006-03-09 Novo Nordisk A/S Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
EA007485B1 (ru) * 2001-02-24 2006-10-27 Берингер Ингельхайм Фарма Гмбх Унд Ко. Кг Производные ксантина, способ их получения, фармацевтическая композиция на их основе и способ ее получения
US6869947B2 (en) * 2001-07-03 2005-03-22 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
ATE395349T1 (de) 2001-08-28 2008-05-15 Schering Corp Polycyclische guanin phosphodiesterase inhibitoren
AU2002331311A1 (en) * 2001-09-19 2003-04-01 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
US6943171B2 (en) 2001-11-09 2005-09-13 Schering Corporation Polycyclic guanine derivative phosphodiesterase V inhibitors
ATE409466T1 (de) * 2002-01-11 2008-10-15 Novo Nordisk As Verfahren und zusammensetzung zur behandlung von diabetes, hypertonie, chronischer herzinsuffizienz und mit flüssigkeitsretention einhergehenden zuständen
JP2004043429A (ja) * 2002-02-25 2004-02-12 Eisai Co Ltd 新規キサンチン誘導体およびdppiv阻害剤
DE60319980T2 (de) * 2002-05-31 2009-04-16 Schering Corporation Xanthin-phosphodiesterase-v-hemmer polymorphe
WO2004009091A1 (en) * 2002-06-17 2004-01-29 Glaxo Group Limited Purine derivatives as liver x receptor agonists
JP4233524B2 (ja) * 2002-08-21 2009-03-04 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 8−[3−アミノ−ピペリジン−1−イル]−キサンチン、その製造およびその薬理組成物としての使用
WO2004033455A2 (en) * 2002-10-08 2004-04-22 Novo Nordisk A/S Hemisuccinate salts of heterocyclic dpp-iv inhibitors
WO2004048379A1 (ja) * 2002-11-01 2004-06-10 Sumitomo Pharmaceuticals Co., Ltd. キサンチン化合物
CA2528385C (en) * 2003-06-06 2011-03-15 Endacea, Inc. A1 adenosine receptor antogonists
CN1860119A (zh) * 2003-07-31 2006-11-08 先灵公司 用于治疗勃起功能障碍的黄嘌呤磷酸二酯酶5抑制剂代谢物及其衍生物
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel

Similar Documents

Publication Publication Date Title
JP2005529934A5 (US07786301-20100831-C00009.png)
JP3703869B2 (ja) ヒドロキシフェニル−1,3,5−トリアジンの製造方法
JP6633539B2 (ja) 2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−1−(5−置換−ピリジン−2−イル)−3−(1h−テトラゾール−1−イル)プロパン−2−オールおよびその調製工程
KR101565169B1 (ko) 인테그라제 억제제의 제조를 위한 방법 및 중간체
EP3376865B1 (en) 4-((6-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1h
JP2005529934A (ja) キサンチンホスホジエステラーゼvインヒビターおよびその前駆物質を調製するプロセス
JP2007153906A (ja) 複素環式化合物のスルフィニル化方法
JP2017504576A5 (US07786301-20100831-C00009.png)
CA2826260C (en) Methods of making hiv attachment inhibitor prodrug compound and intermediates
CA2934531A1 (en) Process methods for phosphatidylinositol 3-kinase inhibitors
WO2007053730A1 (en) PROCESS FOR THE PREPARATION OF (ω -AMINOALKYLAMINO)ALKYL HALIDES AND CONVERSION TO AMIFOSTINE
CZ292092B6 (cs) Deriváty triazolopyrimidinu
KR20140040766A (ko) 팔리페리돈의 제조방법
JP7448532B2 (ja) ピペラジニル-エトキシ-ブロモフェニル誘導体の新しい合成方法及びそれらを含有する化合物の製造におけるその応用
JP2012512237A (ja) アナグレリドの製造法
JP4641795B2 (ja) 1,2,4−トリアゾリルメチルオキシラン類の製造方法
JP4667575B2 (ja) 1,3−ジアルキルイミダゾリウムヨウ素塩の製造方法
JP4902976B2 (ja) フッ素化された1,3−ベンゾジオキサン、その製造及び使用
JP2022537737A (ja) 3,3’-ジデオキシ-3,3’-ビス-[4-(3-フルオロフェニル)-1h-1,2,3-トリアゾル-1-イル]-1,1’-スルファンジイル-ジ-ベータ-d-ガラクトピラノシドの大規模方法
JPH0662577B2 (ja) 1−メチル−5−ヒドロキシピラゾ−ルの製造法
JP3477631B2 (ja) 1,3−ビス(3−アミノプロピル)−1,1,3,3−テトラオルガノジシロキサンの精製方法
EA006706B1 (ru) Производные n-аминоимидазола, ингибирующие вич
KR20220147435A (ko) 카르밤산염 화합물의 제조방법
JP4673313B2 (ja) 1、2、3、9−テトラヒドロ−9−メチル−3−[(2−メチル−1h−イミダゾール−1−イル)メチル]−4h−カルバゾール−4−オンまたはその塩の製造方法
JPH08208623A (ja) イミダゾール系化合物の製造方法